Effect of long‐term treatment with a small‐molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function

We investigated the long‐term effect of a glucokinase (GK) activator (GKA) on the changes in hepatic gene expression, glucose metabolism, lipid profiles and hepatic function in wild‐type mice and the haploinsufficiency of β‐cell‐specific GK mice on a high‐fat (HF) diet. Twenty weeks of GKA treatment had no effect on hepatic GK activity or expression of genes related to glucose or lipid metabolism, suggesting that chronic GK activation by GKA showed a sustained reduction of ambient blood glucose levels without causing significant impact on hepatic lipid and glucose metabolisms. Furthermore, GKA exerted glucose‐lowering efficacy lasted for up to 40 weeks without increasing bodyweight or exerting adverse effects on lipid metabolism or hepatic function in either genotype on the HF diet. The present results show that GKA is capable of chronically improving glucose metabolism in mice on the HF diet without exerting a harmful influence on their lipid profile or hepatic function. (J Diabetes Invest,doi: 10.1111/j.2040‐1124.2011.00103.x, 2011)

[1]  Y. Terauchi,et al.  Impact of small-molecule glucokinase activator on glucose metabolism and beta-cell mass. , 2009, Endocrinology.

[2]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[3]  H. Aburatani,et al.  Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. , 2007, The Journal of clinical investigation.

[4]  A. Kadotani,et al.  An Allosteric Activator of Glucokinase Impairs the Interaction of Glucokinase and Glucokinase Regulatory Protein and Regulates Glucose Metabolism* , 2006, Journal of Biological Chemistry.

[5]  Yun-ping Zhou,et al.  A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat. , 2010, European journal of pharmacology.

[6]  J. Grippo,et al.  Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. , 2001, Diabetes.

[7]  N. Hashimoto,et al.  Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy. , 2009, Bioorganic & medicinal chemistry.

[8]  M. Magnuson,et al.  The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. , 2006, Diabetes.

[9]  J. Grippo,et al.  Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy , 2003, Science.

[10]  J. Agudo,et al.  Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance , 2003, Diabetologia.

[11]  F. Matschinsky,et al.  Assessing the potential of glucokinase activators in diabetes therapy , 2009, Nature Reviews Drug Discovery.